Open Questions: Hypotheses

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
43 questions found for field 'Hypotheses'
open ⚖ 1500
How does age affect neurotrophin therapy response?
📑 0.50 💥 0.50
open ⚖ 1500
What molecular pathways link different proteinopathies?
📑 0.50 💥 0.50
open ⚖ 1500
Can we prevent secondary proteinopathy after primary diagnosis?
📑 0.50 💥 0.50
open ⚖ 1500
What determines which protein pathology develops first?
📑 0.50 💥 0.50
open ⚖ 1500
How do we model co-pathology in experimental systems?
📑 0.50 💥 0.50
open ⚖ 1500
Strain-specific targeting
📑 0.50 💥 0.50
open ⚖ 1500
Early intervention
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
What is the optimal timing for neurotrophin intervention relative to disease stage?
📑 0.50 💥 0.50
open ⚖ 1500
Can combination therapy (GDNF + anti-α-syn) provide synergistic benefits?
📑 0.50 💥 0.50
open ⚖ 1500
How do genetic subtypes (LRRK2, GBA, SNCA) affect neurotrophin response?
📑 0.50 💥 0.50
open ⚖ 1500
What are the long-term safety implications of sustained GDNF expression?
📑 0.50 💥 0.50
open ⚖ 1500
Can peripheral biomarkers predict CNS neurotrophin deficiency?
📑 0.50 💥 0.50
open ⚖ 1500
What is the minimum effective dose for different delivery methods?
📑 0.50 💥 0.50
open ⚖ 1500
Can biomarker panels identify ideal candidates for specific therapies?
📑 0.50 💥 0.50
open ⚖ 1500
Does SG dysfunction precede alpha-synuclein pathology in humans?
📑 0.50 💥 0.50
open ⚖ 1500
Can SG modulation slow disease progression in PD models?
📑 0.50 💥 0.50
open ⚖ 1500
What are the specific vulnerabilities of dopaminergic neurons to SG pathology?
📑 0.50 💥 0.50
open ⚖ 1500
How do genetic risk factors (LRRK2, GBA, SNCA) interact with SG pathways?
📑 0.50 💥 0.50
open ⚖ 1500
Can biomarkers detect SG dysfunction in living patients?
📑 0.50 💥 0.50
open ⚖ 1500
Structural Biology
📑 0.50 💥 0.50
open ⚖ 1500
Human Biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Genetic Stratification
📑 0.50 💥 0.50
open ⚖ 1500
Combination Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Improved dual-pathology models
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-driven trials
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Precision medicine
📑 0.50 💥 0.50
open ⚖ 1500
Engineered neurotrophins
📑 0.50 💥 0.50
open ⚖ 1500
Exosome-based delivery
📑 0.50 💥 0.50
open ⚖ 1500
Gene editing
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-driven patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Small molecule Trk modulators
📑 0.50 💥 0.50
open ⚖ 1500
Nanoparticle encapsulation
📑 0.50 💥 0.50
open ⚖ 1500
Single-cell proteomics
📑 0.50 💥 0.50
open ⚖ 1500
Spatial transcriptomics
📑 0.50 💥 0.50
open ⚖ 1500
Cryo-EM structures
📑 0.50 💥 0.50
open ⚖ 1500
Systems biology
📑 0.50 💥 0.50
open ⚖ 1500
Common pathway targeting
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-driven trials
📑 0.50 💥 0.50
open ⚖ 1500
Stage-specific interventions
📑 0.50 💥 0.50
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map